# Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

> **NCT02386566** · — · COMPLETED · sponsor: **Biogen** · enrollment: 48 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT02386566
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-20
- **Primary completion:** 2018-01-28
- **Final completion:** 2018-01-28
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386566, "Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02386566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*